[1] Reya T, Morrison SJ, Clarke MF, et al. Stem cells, cancer, and cancer stem cells[J]. Nature, 2001, 414: 105-111. [2] Brown HK, Tellez-Gabriel M, Heymann D. Cancer stem cells in osteosarcoma[J]. Cancer Lett, 2017, 386: 189-195. [3] Castelli G, Pelosi E, Testa U. Liver cancer: molecular characterization, clonal evolution and cancer stem cells[J]. Cancers (Basel), 2017, 9:127.doi:10.3390/cancers9090127. [4] Markowska A, Sajdak S, Huczyński A, et al. Ovarian cancer stem cells: a target for oncological therapy[J]. Adv Clin Exp Med, 2018, 27: 1017-1020. [5] Sancho P, Barneda D, Heeschen C. Hallmarks of cancer stem cell metabolism[J]. Br J Cancer, 2016, 114: 1305-1312. [6] Yan Y, Zuo X, Wei D. Concise review: emerging role of CD44 in cancer stem cells: a promising biomarker and therapeutic target[J]. Stem Cells Transl Med, 2015, 4: 1033-1043. [7] Pajonk F, Vlashi E, McBride WH. Radiation resistance of cancer stem cells: the 4 R's of radiobiology revisited[J]. Stem Cells, 2010, 28: 639-648. [8] Gajewski TF, Schreiber H, Fu YX. Innate and adaptive immune cells in the tumor microenvironment[J]. Nat Immunol, 2013, 14: 1014-1022. [9] Shen H, Sun T, Hoang HH, et al. Enhancing cancer immunotherapy through nanotechnology-mediated tumor infiltration and activation of immune cells[J]. Semin Immunol, 2017, 34: 114-122. [10] Stanton SE, Disis ML. Clinical significance of tumor-infiltrating lymphocytes in breast cancer[J]. J Immunother Cancer, 2016, 4: 59.doi:10.1186/s40425-016-0165-6. [11] Ribas A, Wolchok JD. Cancer immunotherapy using checkpoint blockade[J]. Science, 2018, 359: 1350-1355. [12] de Miguel M, Calvo E. Clinical challenges of immune checkpoint inhibitors[J]. Cancer Cell, 2020, 38: 326-333. [13] 白丽鹏, 陈翀, 刘妍,等.LIN28B调控miRNAs维持MCF-7肿瘤干细胞的干性特征[J]. 基础医学与临床,2015, 35: 754-760. [14] 曹峰琦,陈翀,刘妍,等.肿瘤pH微环境通过激活β-catenin/TCF4增强人乳腺癌肿瘤细胞的干性[J]. 基础医学与临床,2014, 34: 622-627. [15] Agudo J, Park ES, Rose SA, et al. Quiescent tissue stem cells evade immune surveillance[J]. Immunity, 2018, 48: 271-285. |